PubRank

René Bernards

Author PubWeight™ 330.34‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 71.36
2 A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 58.15
3 A system for stable expression of short interfering RNAs in mammalian cells. Science 2002 35.21
4 A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007 11.21
5 Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012 9.39
6 A genomic and functional inventory of deubiquitinating enzymes. Cell 2005 9.36
7 A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004 8.67
8 An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008 8.12
9 Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002 7.88
10 Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003 6.53
11 Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 2006 5.96
12 Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol 2006 4.67
13 Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006 4.57
14 Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006 4.54
15 The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 2005 4.40
16 The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 2005 4.29
17 Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008 4.24
18 MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 2012 4.01
19 Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 2008 3.74
20 Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008 3.70
21 Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004 3.23
22 ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009 2.93
23 An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006 2.91
24 The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005 2.73
25 Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem 2003 2.14
26 NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010 1.81
27 Expression profiling predicts outcome in breast cancer. Breast Cancer Res 2002 1.81
28 The translation initiation factor 3f (eIF3f) exhibits a deubiquitinase activity regulating Notch activation. PLoS Biol 2010 1.77
29 A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling. Genes Dev 2002 1.65
30 E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell 2002 1.59
31 Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2004 1.56
32 Re-evaluating cell-cycle regulation by E2Fs. Cell 2006 1.46
33 TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence. J Biol Chem 2001 1.46
34 E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains. Oncogene 2004 1.44
35 Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 2013 1.38
36 Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells. Mol Cell 2005 1.34
37 Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 2009 1.33
38 A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One 2009 1.29
39 Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov 2014 1.27
40 A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat Cell Biol 2002 1.25
41 New tools for functional mammalian cancer genetics. Nat Rev Cancer 2003 1.22
42 PR72, a novel regulator of Wnt signaling required for Naked cuticle function. Genes Dev 2005 1.21
43 Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle 2006 1.17
44 TSPYL5 suppresses p53 levels and function by physical interaction with USP7. Nat Cell Biol 2010 1.13
45 A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 2006 1.09
46 Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cytostatic activity. J Biol Chem 2008 1.09
47 A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2007 1.07
48 PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle. Proc Natl Acad Sci U S A 2006 1.07
49 Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nat Med 2011 1.05
50 The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling. Mol Cancer Res 2010 1.04
51 Cancer: cues for migration. Nature 2003 0.97
52 A RNA interference screen identifies the protein phosphatase 2A subunit PR55gamma as a stress-sensitive inhibitor of c-SRC. PLoS Genet 2007 0.95
53 UNC45A confers resistance to histone deacetylase inhibitors and retinoic acid. Mol Cancer Res 2009 0.95
54 Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res 2010 0.94
55 An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol 2013 0.93
56 Understanding resistance to targeted cancer drugs through loss of function genetic screens. Drug Resist Updat 2012 0.93
57 High incidence of thymic epithelial tumors in E2F2 transgenic mice. J Biol Chem 2003 0.91
58 Constitutive E2F1 overexpression delays endochondral bone formation by inhibiting chondrocyte differentiation. Mol Cell Biol 2003 0.91
59 TGF-β: an emerging player in drug resistance. Cell Cycle 2013 0.90
60 A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. Mol Oncol 2013 0.90
61 A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-beta. J Biol Chem 2006 0.89
62 Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling. Mol Cancer Res 2008 0.87
63 Interleukin-1R-associated kinase 2 is a novel modulator of the transforming growth factor beta signaling cascade. Mol Cancer Res 2010 0.87
64 Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. Int J Biochem Cell Biol 2008 0.86
65 Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs. Breast Cancer Res Treat 2011 0.86
66 Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E. Carcinogenesis 2009 0.85
67 Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Int J Cancer 2014 0.84
68 Resistance to targeted cancer drugs through hepatocyte growth factor signaling. Cell Cycle 2014 0.84
69 Genetic and functional studies implicate synaptic overgrowth and ring gland cAMP/PKA signaling defects in the Drosophila melanogaster neurofibromatosis-1 growth deficiency. PLoS Genet 2013 0.83
70 Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. Clin Cancer Res 2009 0.80
71 Functional annotation of deubiquitinating enzymes using RNA interference. Methods Enzymol 2005 0.80
72 Wip-ing out cancer. Nat Genet 2004 0.79
73 Cancer: Entangled pathways. Nature 2008 0.79
74 An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression. Oncogene 2004 0.77
75 Functional subtyping of breast cancer. Cancer Discov 2011 0.75
76 Are short-term or long-term recurrence rates more important in breast cancer screening? Ann Intern Med 2008 0.75